• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Genetics Market
    Genetics News
    Genetics Stocks
    • Genetics Market
    • Genetics News
    • Genetics Stocks

    Propanc Receives Patentability Opinion for Cancer Treatment

    Bryan Mc Govern
    Mar. 28, 2017 08:26AM PST
    Genetics Investing

    Propanc Health Group (OTCQB:PPCH) received a recommendation on the patentability of its stem cell-based cancer treatment PRP.

    Propanc Health Group (OTCQB:PPCH) received a recommendation on the patentability of its stem cell-based cancer treatment PRP.
    As quoted in the press release:

    An International Search Report (ISR) and Written Opinion was issued by the International Searching Authority on a Patent Cooperation Treaty (PCT) application recently submitted by the Company. The PCT application covers a method for treating cancer stem cells by administering therapeutically effective amounts of trypsinogen and chymotrypsinogen. The ISR provides a very positive first opinion on the patentability of the claims, where the examiner has considered most claimed subject matter to be novel and inventive.
    “We are very pleased with this important step in determining the patentability of a key patent in our portfolio for our lead product, PRP,” said James Nathanielsz, Propanc’s Chief Executive Officer. “Targeting and eradicating cancer stem cells, whilst minimizing toxic effects towards healthy cells, is fundamental to preventing and treating metastatic cancer, which is the main cause of patient death for sufferers. We firmly believe we have an exciting and innovative approach to address this key issue and look forward to entering the national phase for this key patent in all major jurisdictions around the world.”
    Cancer stem cells are immortal, tumour-initiating cells that have the capacity to self-renew and can generate different cell types (i.e. pluripotent). Cancer stem cells are found in multiple malignancies, including leukemia and many solid tumours and, given their stem-cell like properties, are thought to be the basis for tumour initiation, development, metastasis and recurrence. They represent only a small fraction of the cancer cells within a tumour and can remain dormant for extended periods of time, thereby evading conventional therapies such as chemotherapy and radiotherapy, which target rapidly dividing cells. Consequently, a priority for improving cancer treatment and reducing the risk of cancer relapse is to develop new strategies that selectively target cancer stem cell eradication while sparing normal stem cells.
    The Company’s lead product, PRP, is a novel, patented, formulation consisting of two pancreatic proenzymes, trypsinogen and chymotrypsinogen. Currently in formal preclinical development and progressing towards First-In-Man studies, PRP aims to prevent tumor recurrence and metastasis in solid tumors. Eighty percent of all cancers are solid tumors and metastasis is the main cause of patient death from cancer. The Company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.
    To view Propanc’s “Mechanism of Action” video on anti-cancer product candidate, PRP, please click on the following link: https://www.propanc.com/news-media/video
    To be added to Propanc’s email distribution list, please email PPCH@kcsa.com with “Propanc” in the subject line.
    About Propanc:
    Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.

    Click here to read the full press release.

    cancer treatmentstem cell treatmentproduct candidate
    The Conversation (0)

    Go Deeper

    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports world

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Genetics Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES